Business Context and Reporting Period
Company: Nano-X Imaging Ltd. (NNOX)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Nano-X is an Israeli medical imaging company developing the Nanox System, which includes the Nanox.ARC and Nanox.ARC X (3D digital tomosynthesis systems) and Nanox.CLOUD (cloud software). The company also operates teleradiology services (USARAD), AI imaging solutions (Nanox AI), and healthcare IT services (Nanox Health IT). The company is in the initial launch stage of commercializing its imaging hardware.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $13.0 million | $11.3 million | $9.9 million |
| Net Loss | $(75.0) million | $(53.5) million | $(60.8) million |
| Operating Loss | $(78.2) million | $(56.7) million | $(62.6) million |
| Cash Flow from Operations | $(40.8) million | $(36.6) million | $(44.8) million |
| Cash & Equivalents (End of Period) | $49.2 million | $39.3 million | $56.4 million |
| Working Capital | $50.0 million | $64.7 million | $73.1 million |
| Accumulated Deficit | $(448.8) million | $(373.7) million | $(320.2) million |
Revenue Breakdown (2025): Teleradiology services ($11.6M), AI solutions ($1.0M), and Scan services/Nanox.ARC sales ($0.5M).
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $21.5 million (40%) compared to 2024. This was primarily driven by a non-cash impairment charge of $17.5 million related to the write-down of the chip manufacturing line at the Korean fabrication facility as part of a restructuring plan.
- Revenue Growth: Total revenue increased by 15% to $13.0 million, driven by growth in teleradiology services and the acquisition of Nanox Health IT (Vaso Healthcare IT Corp.) in November 2025.
- Restructuring: The company adopted a plan to close its chip manufacturing line in South Korea and transition to an outsourced manufacturing model to improve gross margins and reduce capital expenditures. This resulted in the significant impairment charge noted above.
- Capital Raises: The company raised approximately $21.4 million in net proceeds during 2025 through the issuance of ordinary shares, including a registered direct offering in November 2025 raising ~$15 million gross.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The independent auditor's report includes an explanatory paragraph regarding this uncertainty. Management estimates current cash resources are insufficient to fund operations for at least one year from the issuance date without additional financing.
- Commercialization Status: While the company has received FDA 510(k) clearances for the Nanox.ARC, Nanox.ARC X, and TAP2D, and a CE mark for the Nanox.ARC, most deployed systems have not yet begun generating revenue. Revenue recognition depends on system activations and the performance of distribution partners.
- Key Risks:
- Liquidity: Continued need for significant additional financing to fund operations and commercialization.
- Regulatory & Reimbursement: Uncertainty regarding third-party payor coverage and reimbursement for the Nanox System.
- Geopolitical: Ongoing conflicts in the Middle East (Israel/Hamas/Iran) and Ukraine pose risks to operations, supply chains, and employee safety, though the company states current impact is immaterial.
- Manufacturing: Risks associated with transitioning to third-party manufacturers (Fabrinet, Varex, CEI) and potential yield or quality issues with the MEMS-based X-ray source.
- Legal Proceedings: The company settled a shareholder class action for $8 million (finalized in 2024) and an SEC investigation regarding development cost estimates (settled in 2023). Several malpractice claims related to teleradiology services are pending.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $49.2 million cash balance against the projected burn rate, given the "substantial doubt" going concern warning.
- Revenue Recognition: Confirm the timing of revenue recognition for the ~360 CapEx systems under distribution agreements, as most are not yet revenue-generating.
- Restructuring Impact: Monitor the execution of the manufacturing transition in South Korea and the realization of expected cost savings and gross margin improvements.
- Reimbursement Status: Track progress on securing third-party payor reimbursement codes and coverage for the Nanox System, which is critical for the Subscription (MSaaS) model.
- Geopolitical Exposure: Assess the potential for escalation in the Middle East to impact the company's Israeli headquarters and Korean manufacturing operations.